Skip to content

PTC Therapeutics

US · PTCT #2071 by market cap Listed 1970
63.23 -0.47 -0.74%
Live - 5344 symbols - heartbeat 259s ago · 2026-10-08 08:05
Pre-market 63.62 +0.62%
After-hours 63.23 0.00%
Market cap
5.28B
P/E (TTM)
-103.66
P/B
-31.92
EPS
7.78
Reader sentiment Are you bullish or bearish on PTCT?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.3 percentage points.

Institutional ownership

Held by institutions
122.07% -0.32pp
Institutions
465 -1
As of
2026/Q3 vs. prior period

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Holder types

Mutual Fund91.52%
Hedge Fund19.18%
Public Company7.56%
Individual/Insider2.39%
Private Company2.01%
Government Pension Fund0.96%
Insurance Company0.55%
Family Office/Trust0.11%

Top holders as of 2026-06-30

BlackRock 16.73% · 13.96M sh
RTW Investments, LP 9.28% · 7.75M sh
Janus Henderson Group plc 8.67% · 7.24M sh
Vanguard Portfolio Management, LLC 5.90% · 4.93M sh
State Street Global Advisors 5.51% · 4.60M sh
Vanguard Capital Management, LLC 5.18% · 4.33M sh
Wellington Management Group 4.95% · 4.13M sh
Geode Capital Management, LLC 2.64% · 2.21M sh
The Toronto-Dominion Bank 2.60% · 2.17M sh
Westfield Capital Management Company, L.P. 2.34% · 1.96M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 7 buys · 40 sells

NameRoleStake
Michael Schmertzler Independent Chairperson 1.74%
Matthew Klein Chief Executive Officer 0.19%
Mark Boulding Chief Legal Officer 0.13%
Christine Utter Senior VP, Chief Accounting Officer & Head of People Services 0.05%
Pierre Gravier Chief Financial Officer 0.04%
Lee Golden Chief Medical Officer 0.04%
Eric Pauwels Chief Business Officer 0.03%
Hege Sollie-Zetlmayer Officer 0.02%
Glenn Steele Independent Director 0.02%
Mary Smith Independent Director 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-04 Mark Boulding Chief Legal Officer Intent to Sell (Form 144) -1,638 $64.03
2026-09-29 Glenn Steele Independent Director Derivative Exercise and Sale -12,000 $11.23–65.16
2026-09-16 Michael Schmertzler Independent Chairperson Automatic Disposition -20,000 $66.58–68.45
2026-09-09 Michael Schmertzler Independent Chairperson Automatic Disposition -20,000 $67.34–68.67
2026-08-26 Michael Schmertzler Independent Chairperson Automatic Disposition -25,000 $71.55–73.18
2026-08-19 Michael Schmertzler Independent Chairperson Automatic Disposition -25,000 $70.78–73.67
2026-08-18 Michael Schmertzler Independent Chairperson Intent to Sell (Form 144) -50,000 --
2026-08-16 Mark Boulding Chief Legal Officer Derivative Exercise and Sale -2,813 $25.69–72.90
2026-08-03 Matthew Klein Chief Executive Officer Open Market Disposition -10,292 $68.57
2026-07-27 Hege Sollie-Zetlmayer Officer Other Acquisition +6,000 --
2026-07-27 Hege Sollie-Zetlmayer Officer Other Derivative Acquisition +5,213 $75.39
2026-07-27 Hege Sollie-Zetlmayer Officer Initial Statement of Beneficial 0 --
2026-07-13 Pierre Gravier Chief Financial Officer Open Market Disposition -3,494 $80.35
2026-07-08 Neil Almstead Chief Technical Operations Officer Derivative Exercise and Sale -2,464 $46.54–90.25
2026-07-08 Mary Smith Independent Director Derivative Exercise and Sale -15,834 $42.95–90.00
2026-07-06 Neil Almstead Chief Technical Operations Officer Derivative Exercise and Sale -46,774 $38.10–89.44
2026-07-06 Neil Almstead Chief Technical Operations Officer Intent to Sell (Form 144) -24,613 $88.88
2026-07-05 Mark Boulding Chief Legal Officer Derivative Exercise and Sale -5,079 $39.42–86.38
2026-07-05 Neil Almstead Chief Technical Operations Officer Intent to Sell (Form 144) -22,161 $86.00
2026-06-25 Neil Almstead Chief Technical Operations Officer Derivative Exercise and Sale -8,130 $38.10–85.26

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-10-08 08:05:34 · For reference only, not investment advice and not tailored to your situation.